Atomwise
AI-driven drug discovery platform using machine learning to predict bioactivity of small molecules.
Atomwise invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Learn more at atomwise.com or follow @AtomwiseInc.
Testimonial
Related Companies
GenProof
GenProof generates mathematical proofs that guarantee 100% code correctness
San Francisco, California, United States
Klona Biotech
The future of human tissue replacements using 3D printing
London, United Kingdom
Glīd
Autonomous dual-mode vehicles that seamlessly transition between road and rail to deliver faster, greener, and more resilient first-mile logistics
Shaver Lake, CA
Lyric Bio
Pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies
San Carlos, California
Autolane
The platform orchestrating autonomous vehicles for commerce and ride-hailing
United States
Eywa Biotech
Scaling the production of pharmaceutical-grade psychedelic compounds through synthetic biology
Montevideo, Uruguay · Buenos Aires, Argentina
NLPatent
AI-native patent research and intelligence platform purpose-built to overcome the limitations of traditional patent research.
Toronto, Ontario, Canada
